The subcommittee heard testimony from three panels of doctors, pharmaceutical corporation administrators and public health experts on the prices of prescription drugs. The subcommittee specifically sought to hear testimony on proposals to control the costs of prescription drugs, particularly those developed with federal grants to the pharmaceutical companies.